CeMines公司研制出肺癌诊断试剂盒

 
 
来自扩大临床试验的资料显示：设计用于肺癌诊断的检测试剂盒敏感性和特异性极高。这些资料在2005年5月费城举行的世界生物标志物大会上进行了报道。

CellCorrect LAb检测试剂盒是由CeMines公司(Golden, CO, USA)研制开发的。最新资料还证实了在乳腺、结肠和胃癌患者血液中存在具有诊断意义的自身抗体。该公司宣布完成了涉及转录机制分子的设计与传输的两项申请。CeMines相信这种知识产权将对该公司研制开发不同类型癌症治疗方法中发挥重要作用。

CellCorrect LAb检测自身免疫的改变和血液中疾病相关的自身抗体模式。CellMines公司声称，更进一步的研究证实作为鉴别癌症的生物标志物的特定抗体具有特异性和一致性， 能够作为癌症的诊断检测试验。该公司使用具有产权的生物资讯为基础的统计模式识别应用软件，叫做“分子指纹”软件，该软件能够评估癌症患者中特定抗体模式。
 
Detection Kit to Aid Diagnosis of Lung Cancer
 
New data from an expanded comprehensive clinical study have demonstrated high sensitivity and specificity of a detection kit designed for the diagnosis of lung cancer. The data were presented at the World Biomarker Congress in May 2005 in Philadelphia (PA, USA).

The CellCorrect LAb detection kit was developed by CeMines, Inc. (Golden, CO, USA). The updated data also demonstrated the presence of diagnostically informative autoantibodies in the blood of breast, colon, and stomach cancer patients. The company has announced the filing of two patents claiming specific design and delivery of molecules that interfere with transcriptional mechanisms. CeMines believes this intellectual property will play a key role in the company’s development of drugs to treat different types of cancer.

CellCorrect LAb detects altered autoimmunity and associated patterns of disease-related autoantibodies in the bloodstream. Extensive studies have demonstrated that specific and consistent patterns of certain antibodies have regularly proven their utility as composite biomarkers to characterize cancer, states CeMines, and can therefore be used as diagnostic tests for cancer. The company uses a proprietary bioinformatics-based statistical pattern-recognition application called Molecular Fingerprinting, which evaluates the patterns of certain antibodies in the profiles of cancer patients.